Credit Suisse analyst Lorenzo Biasio maintained a Buy rating on Coherus Biosciences (CHRS – Research Report) yesterday and set a price target of $24.50. The company's shares closed last Thursday at $11.56, close to its 52-week low of $10.53. According to TipRanks.com, Biasio is a 4-star analyst with an average return of 7.3% and a 60.5% success rate. Biasio covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Merck & Company, and Thermo Fisher. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coherus Biosciences with a $24.40 average price target, representing a 107.0% upside.
https://www.tipranks.com/news/blurbs/credit-suisse-thinks-coherus-biosciences-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Coherus BioSciences Charts.
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Coherus BioSciences Charts.